Schroder Investment Management Group Boosts Position in Davita Inc (DVA)
Schroder Investment Management Group raised its stake in shares of Davita Inc (NYSE:DVA) by 102.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 265,663 shares of the company’s stock after purchasing an additional 134,558 shares during the period. Schroder Investment Management Group’s holdings in Davita were worth $18,636,000 as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. bought a new stake in Davita during the second quarter valued at about $3,421,000. OppenheimerFunds Inc. grew its holdings in Davita by 58.7% during the second quarter. OppenheimerFunds Inc. now owns 4,066,317 shares of the company’s stock valued at $282,365,000 after purchasing an additional 1,504,347 shares during the period. Tibra Equities Europe Ltd bought a new stake in Davita during the second quarter valued at about $1,627,000. Alps Advisors Inc. grew its holdings in Davita by 11.1% during the second quarter. Alps Advisors Inc. now owns 10,781 shares of the company’s stock valued at $749,000 after purchasing an additional 1,080 shares during the period. Finally, Hikari Tsushin Inc. grew its holdings in Davita by 10.5% during the second quarter. Hikari Tsushin Inc. now owns 74,410 shares of the company’s stock valued at $5,624,000 after purchasing an additional 7,050 shares during the period. 87.71% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on DVA shares. Zacks Investment Research lowered Davita from a “buy” rating to a “hold” rating in a report on Wednesday, August 1st. JPMorgan Chase & Co. raised Davita from an “underweight” rating to a “neutral” rating in a report on Thursday, September 13th. Finally, William Blair reissued a “buy” rating on shares of Davita in a report on Wednesday, June 6th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $82.13.
Davita (NYSE:DVA) last released its quarterly earnings data on Wednesday, August 1st. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.88 billion. Davita had a return on equity of 14.49% and a net margin of 4.30%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.92 earnings per share. equities research analysts predict that Davita Inc will post 4 EPS for the current year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: How Do Tariffs Affect Trade Balances?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.